vs
碧迪（BDX）与ICAHN ENTERPRISES L.P.（IEP）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是ICAHN ENTERPRISES L.P.的1.9倍（$5.3B vs $2.7B），碧迪净利率更高（7.3% vs 0.0%，领先7.2%），ICAHN ENTERPRISES L.P.同比增速更快（5.4% vs -0.4%），碧迪自由现金流更多（$549.0M vs $-496.0M），过去两年ICAHN ENTERPRISES L.P.的营收复合增速更高（4.5% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
伊坎企业有限合伙企业是美国上市的 Master 有限合伙企业与多元化集团，总部位于佛罗里达州阳光岛海滩的弥尔顿大厦。公司投资布局覆盖能源、汽车、食品包装、金属、房地产、家居时尚等多个领域，由知名投资人卡尔·伊坎控股，其持股比例达86%。
BDX vs IEP — 直观对比
营收规模更大
BDX
是对方的1.9倍
$2.7B
营收增速更快
IEP
高出5.7%
-0.4%
净利率更高
BDX
高出7.2%
0.0%
自由现金流更多
BDX
多$1.0B
$-496.0M
两年增速更快
IEP
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $2.7B |
| 净利润 | $382.0M | $1.0M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 0.6% |
| 净利率 | 7.3% | 0.0% |
| 营收同比 | -0.4% | 5.4% |
| 净利润同比 | 24.0% | 101.0% |
| 每股收益（稀释后） | $1.34 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXIEP
| Q4 25 | $5.3B | $2.7B | ||
| Q3 25 | $5.9B | $2.7B | ||
| Q2 25 | $5.5B | $2.4B | ||
| Q1 25 | $5.3B | $1.9B | ||
| Q4 24 | $5.2B | $2.6B | ||
| Q3 24 | $5.4B | $2.8B | ||
| Q2 24 | $5.0B | $2.2B | ||
| Q1 24 | $5.0B | $2.5B |
净利润BDXIEP
| Q4 25 | $382.0M | $1.0M | ||
| Q3 25 | $493.0M | $287.0M | ||
| Q2 25 | $574.0M | $-165.0M | ||
| Q1 25 | $308.0M | $-422.0M | ||
| Q4 24 | $303.0M | $-98.0M | ||
| Q3 24 | $400.0M | $22.0M | ||
| Q2 24 | $487.0M | $-331.0M | ||
| Q1 24 | $537.0M | $-38.0M |
毛利率BDXIEP
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXIEP
| Q4 25 | 10.5% | 0.6% | ||
| Q3 25 | 11.8% | 19.7% | ||
| Q2 25 | 16.0% | -10.4% | ||
| Q1 25 | 10.4% | -35.0% | ||
| Q4 24 | 8.8% | -5.2% | ||
| Q3 24 | 11.4% | 2.4% | ||
| Q2 24 | 12.1% | -21.9% | ||
| Q1 24 | 14.5% | -0.8% |
净利率BDXIEP
| Q4 25 | 7.3% | 0.0% | ||
| Q3 25 | 8.4% | 10.5% | ||
| Q2 25 | 10.4% | -7.0% | ||
| Q1 25 | 5.8% | -22.6% | ||
| Q4 24 | 5.9% | -3.8% | ||
| Q3 24 | 7.4% | 0.8% | ||
| Q2 24 | 9.8% | -15.0% | ||
| Q1 24 | 10.6% | -1.5% |
每股收益（稀释后）BDXIEP
| Q4 25 | $1.34 | — | ||
| Q3 25 | $1.71 | — | ||
| Q2 25 | $2.00 | — | ||
| Q1 25 | $1.07 | — | ||
| Q4 24 | $1.04 | — | ||
| Q3 24 | $1.37 | — | ||
| Q2 24 | $1.68 | — | ||
| Q1 24 | $1.85 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $25.3B | — |
| 总资产 | $54.8B | $14.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDXIEP
| Q4 25 | $740.0M | $1.4B | ||
| Q3 25 | $641.0M | $1.8B | ||
| Q2 25 | $735.0M | $1.8B | ||
| Q1 25 | $667.0M | $2.2B | ||
| Q4 24 | $711.0M | $2.6B | ||
| Q3 24 | $1.7B | $2.3B | ||
| Q2 24 | $4.5B | $2.2B | ||
| Q1 24 | $2.3B | $2.5B |
股东权益BDXIEP
| Q4 25 | $25.3B | — | ||
| Q3 25 | $25.4B | — | ||
| Q2 25 | $25.5B | — | ||
| Q1 25 | $25.2B | — | ||
| Q4 24 | $25.2B | — | ||
| Q3 24 | $25.9B | — | ||
| Q2 24 | $25.9B | — | ||
| Q1 24 | $25.6B | — |
总资产BDXIEP
| Q4 25 | $54.8B | $14.2B | ||
| Q3 25 | $55.3B | $14.8B | ||
| Q2 25 | $54.9B | $14.8B | ||
| Q1 25 | $54.5B | $15.5B | ||
| Q4 24 | $54.7B | $16.3B | ||
| Q3 24 | $57.3B | $17.4B | ||
| Q2 24 | $55.6B | $18.0B | ||
| Q1 24 | $54.2B | $20.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $-421.0M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $-496.0M |
| 自由现金流率自由现金流/营收 | 10.5% | -18.4% |
| 资本支出强度资本支出/营收 | 2.1% | 2.8% |
| 现金转化率经营现金流/净利润 | 1.72× | -421.00× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $-654.0M |
8季度趋势，按日历期对齐
经营现金流BDXIEP
| Q4 25 | $657.0M | $-421.0M | ||
| Q3 25 | $1.4B | $15.0M | ||
| Q2 25 | $1.2B | $275.0M | ||
| Q1 25 | $164.0M | $-182.0M | ||
| Q4 24 | $693.0M | $244.0M | ||
| Q3 24 | $1.2B | $-54.0M | ||
| Q2 24 | $1.3B | $893.0M | ||
| Q1 24 | $514.0M | $-251.0M |
自由现金流BDXIEP
| Q4 25 | $549.0M | $-496.0M | ||
| Q3 25 | $1.0B | $-67.0M | ||
| Q2 25 | $1.0B | $179.0M | ||
| Q1 25 | $35.0M | $-270.0M | ||
| Q4 24 | $588.0M | $156.0M | ||
| Q3 24 | $882.0M | $-112.0M | ||
| Q2 24 | $1.1B | $827.0M | ||
| Q1 24 | $380.0M | $-319.0M |
自由现金流率BDXIEP
| Q4 25 | 10.5% | -18.4% | ||
| Q3 25 | 17.0% | -2.5% | ||
| Q2 25 | 19.0% | 7.6% | ||
| Q1 25 | 0.7% | -14.5% | ||
| Q4 24 | 11.4% | 6.1% | ||
| Q3 24 | 16.2% | -4.0% | ||
| Q2 24 | 22.4% | 37.6% | ||
| Q1 24 | 7.5% | -12.9% |
资本支出强度BDXIEP
| Q4 25 | 2.1% | 2.8% | ||
| Q3 25 | 6.0% | 3.0% | ||
| Q2 25 | 3.2% | 4.1% | ||
| Q1 25 | 2.4% | 4.7% | ||
| Q4 24 | 2.0% | 3.4% | ||
| Q3 24 | 5.4% | 2.1% | ||
| Q2 24 | 3.6% | 3.0% | ||
| Q1 24 | 2.7% | 2.8% |
现金转化率BDXIEP
| Q4 25 | 1.72× | -421.00× | ||
| Q3 25 | 2.75× | 0.05× | ||
| Q2 25 | 2.12× | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | 2.94× | -2.45× | ||
| Q2 24 | 2.66× | — | ||
| Q1 24 | 0.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
IEP
| Public Utilities Inventory Petroleum Products | $1.6B | 61% |
| Other | $381.0M | 14% |
| Automotive Services | $345.0M | 13% |
| Nitrogen Fertilizer Products | $131.0M | 5% |
| Food Packaging Segment | $82.0M | 3% |
| Home Fashion Segment | $45.0M | 2% |
| Renewable Products | $32.0M | 1% |
| Pharma Segment | $23.0M | 1% |
| Holding Company | $11.0M | 0% |
